Surgery Partners (SGRY) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Surgery Partners published the results on November 9, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Surgery Partners reports EPS two ways: GAAP, under the accounting rules every US filer follows, and Adjusted net income per share, diluted, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Surgery Partners sold its Idaho Falls hospitals (Mountain View Hospital and Idaho Falls Community Hospital) to Intermountain Health on September 14, 2026, so Q3 2026 includes them only through that date.
• Surgery Partners reports one segment, Surgical Facilities. The payor table comes from its 10-Q and covers patient service revenues of consolidated facilities, plus other service revenues.
• Surgery Partners has agreed to be acquired by HealthSpan Partners and, while the deal is pending, gives no guidance and held no earnings call for Q3 2026.

Source: Surgery Partners Q3 2026 results, November 9, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Surgery Partners splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Surgery Partners's Private insurance revenue was $380 million in Q3 2026, down 6% from $404 million in Q3 2025, 47% of total revenue.
• Surgery Partners's Government revenue was $380 million in Q3 2026, up 9% from $348 million in Q3 2025, 47% of total revenue.
• Surgery Partners's Self-pay revenue was $15.3 million in Q3 2026, down 40% from $25.5 million in Q3 2025, 2% of total revenue.
• Surgery Partners's Other revenue was $22.8 million in Q3 2026, up 8% from $21.2 million in Q3 2025, 3% of total revenue.
• Surgery Partners's Other service revenues revenue was $17.3 million in Q3 2026, down 25% from $23.0 million in Q3 2025, 2% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenues and diluted net loss per share attributable to common stockholders, each as first reported in that quarter's release.

We do not hold a confirmed date for Surgery Partners's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 9, 2026

Surgery Partners earns almost all of its revenue from facility fees: patient service revenues were $798.0 million of $815.3 million in Q3 2026, or 97.9%. The fee usually covers the operating room, recovery room, special equipment, medical supplies, nursing staff and medications, and normally excludes the professional fees of the surgeon, anesthesiologist or other attending physician. (Surgery Partners Form 10-Q, Q3 2026, Nov 9, 2026)

Revenues fell 0.8% from $821.5 million because Surgery Partners sold its Idaho Falls hospitals to Intermountain Health on September 14, 2026, for aggregate consideration of about $796.6 million. In facilities comparable across both periods, same-facility revenues rose 6.0%, from a 5.8% increase in revenue per case and a 0.2% increase in cases. (Surgery Partners Q3 2026 release, Nov 9, 2026; Surgery Partners Form 10-Q, Q3 2026, Nov 9, 2026)

Government payors overtook private insurance at Surgery Partners' consolidated facilities in the quarter. Government patient service revenues were $380.3 million, 47.7% of the total, against $347.5 million (43.5%) a year earlier, while private insurance was $379.6 million (47.6%), against $404.3 million (50.6%). Self-pay fell to $15.3 million from $25.5 million. (Surgery Partners Form 10-Q, Q3 2026, Nov 9, 2026)

Surgery Partners had 173 surgical facilities at September 30, 2026, 115 of them consolidated, against 165 and 114 a year earlier. They mainly perform non-emergency procedures in orthopedics and pain management, ophthalmology, gastroenterology and general surgery. Reported cases fell to 159,070 from 166,106, while revenue per case rose to $5,125 from $4,946. (Surgery Partners Q3 2026 release, Nov 9, 2026; Surgery Partners Form 10-K, 2025, Mar 2, 2026)

Surgery Partners reported a net loss attributable to the company of $21.1 million in Q3 2026, or $0.16 per diluted share, against a loss of $22.7 million, or $0.18, a year earlier. Consolidated net income was $14.1 million, but $35.2 million went to non-controlling interests, the physicians and in some cases health systems that co-own facilities Surgery Partners consolidates. (Surgery Partners Q3 2026 release, Nov 9, 2026)

Adjusted net income per diluted share was $0.16, against $0.13. Surgery Partners' adjusted measure removes non-controlling interests' share and excludes transaction and integration costs ($22.6 million, including $14.1 million of M&A costs), equity-based compensation ($6.0 million), litigation settlements and other litigation costs ($5.9 million), a $3.7 million loss on debt extinguishment and $2.9 million of net losses on disposals, consolidations and deconsolidations. (Surgery Partners Q3 2026 release, Nov 9, 2026)

Interest expense, net fell to $67.9 million from $74.9 million. Long-term debt less current maturities was $2,998.7 million at September 30, 2026, down from $3,602.9 million at December 31, 2025, and paydowns of long-term debt in the first nine months were $398.2 million higher than a year earlier. Diluted weighted average shares were 128,865 thousand, against 127,206 thousand. (Surgery Partners Q3 2026 release, Nov 9, 2026; Surgery Partners Form 10-Q, Q3 2026, Nov 9, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Surgery Partners no longer provides forward-looking guidance and did not host a Q3 2026 earnings call, because of its pending acquisition by HealthSpan Partners. On November 9, 2026 it announced an amended merger agreement that raises the price to $25.00 per share in cash, an enterprise value of up to about $6.0 billion, after it received an unsolicited competing proposal from a third party. (Surgery Partners Q3 2026 release, Nov 9, 2026)

Under the amendment, Surgery Partners stockholders other than affiliates of Bain Capital Private Equity receive monthly payments at a rate of 10% a year on the $25.00 price if stockholders approve the merger but it has not closed by March 1, 2027. Surgery Partners still expects the merger to close in the first quarter of 2027, subject to stockholder approval and regulatory approvals. (Surgery Partners Q3 2026 release, Nov 9, 2026)

A consensus figure is the average of the models published by the analysts who cover Surgery Partners, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Surgery Partners's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning SGRY is on is SGRY a buy or a sell?, what analysts expect next is on the SGRY forecast, and what the company does is on the Surgery Partners (SGRY) stock page.

Every number on this page can be traced to a document Surgery Partners published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.